Ingenia Therapeutics has entered the second day of its IPO subscription. Here is a summary of the key information regarding this subscription, market expectations, and investment considerations.

• *[Key Subscription and IPO Schedule]**
• Offer price: 12,000 KRW
• Minimum subscription unit: 20 shares (120,000 KRW)
• Shares allocated to retail investors: 1.25 million shares
• Demand forecasting competition rate: 50.40 to 1
• Lead underwriter: Samsung Securities
• Total subscription deposit: 13.4 billion KRW
• Expected listing date: August 18

As of 12:30 PM, the real-time equal allocation share count stands at 41.

[Company Overview and Technological Capabilities] Ingenia Therapeutics is a company that develops technologies and substances to repair microvessels when they are damaged or in an abnormal state. Its primary target diseases include ocular diseases, kidney diseases, cardiovascular diseases, and brain diseases. To date, the company has a track record of obtaining U.S. FDA approval for more than 10 types of antibodies and compounds and selling them in the anticancer and ophthalmic disease markets. It has also developed two core technologies, which originated from researchers at KAIST and the Institute for Basic Science.

• *[Recent IPO Market Trends]**
• Looking at recent trends in the IPO market, there is a significant difference in opening price returns across individual stocks.
• Lemedik: Opening price return of 48.55%
• StradVision: Opening price return of -8.17% (negative)
• Madup: Opening price return of 178.12% (based on the listing date of July 1)
• Lemon Healthcare and others: Opening price returns have been relatively favorable

As shown, results have been mixed depending on market sentiment, requiring thorough review when making investment decisions.

[Investment Considerations] While the success of Ingenia Therapeutics' subscription depends to some extent on the equal allocation share count, the equal allocation number is not everything. Market conditions on the day of listing also have a significant impact on the opening price return and cannot be ignored. A cautious approach considering comprehensive market conditions is advised.

[This article was written for informational purposes and does not constitute investment advice or a buy/sell recommendation for any specific stock. Stocks may exhibit high volatility due to changes in supply and demand. The final decision and responsibility for investments lie with the investor.]